BioXcel Therapeutics Inc
BTAI
查看详细走势图
1.500USD
+0.130+9.49%
收盘 02/06, 16:00（美东）报价延迟15分钟
29.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.49%
5天
-5.66%
1月
-26.47%
6月
-56.01%
今年开始到现在
-6.25%
1年
-43.18%
查看详细走势图
TradingKey BioXcel Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
BioXcel Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名122/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价14.60。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioXcel Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
BioXcel Therapeutics Inc亮点
亮点风险
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
业绩高增长
公司营业收入稳步增长，连续3年增长504.27%
业绩增长期
公司处于发展阶段，最新年度总收入2.27M美元
估值高估
公司最新PE估值-0.00，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值292.75K
活跃度增加
近期活跃度增加，过去20天平均换手率-0.27
分析师目标
根据
5
位分析师
买入
评级
14.600
目标均价
+879.87%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioXcel Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioXcel Therapeutics Inc简介
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
公司代码BTAI
公司BioXcel Therapeutics Inc
CEOMehta (Vimal)
网址https://www.bioxceltherapeutics.com/
相关品种
